Chantix Litigation Alabama | Chantix Lawyer

Chantix Litigation Alabama: The Lawsuits Keep Adding Up

J. Cooper Carlisle | June 6th, 2011

Lawsuits continue to join the growing Chantix litigation in Alabama, nearly two years after that court was designated as the official location for all federal cases involving Chantix and its serious side effects.

1200 Lawsuits comprise Chantix litigation in Alabama

As of January, 2011, 1,200 Chantix lawsuits were consolidated in the Northern District of Alabama, where they are being overseen in a process called multidistrict litigation (MDL) by Judge Inge P. Johnson.

Since then,  Chantix lawyers have aggressively filed side effects lawsuits on behalf of the injured.

Latest Chantix lawsuit joins MDL

The latest lawsuit to join the MDL is a claim filed by a Chantix lawyer in West Virginia on behalf of plaintiff Peggy E. Parsley. The lawyer filed a motion to keep the lawsuit in West Virginia, claiming Parsley’s circumstances precluded her from the class of plaintiffs involved in the MDL, but the judicial panel overseeing federal Chantix litigation disagreed.

On May 20, 2011the suit was forwarded to the Northern District of Alabama in a transfer order handed down by the Judicial Panel on Multidistrict Litigation (JPML).

Consolidation with Chantix murder-suicide case

That lawsuit will be consolidated alongside one filed on May 9 by a Chantix lawyer representing the parents of a couple involved in a murder-suicide blamed on Chantix. That lawsuit, which seeks damages to compensate 4 children left behind, was filed in the Western District of Pennsylvania.

Various other Chantix lawsuits involving aggressive behavior and serious injury may have joined the litigation since official numbers were last released by the Northern District of Alabama. It is unclear when the court will next report how many lawsuits are consolidated in the Chantix litigation in Alabama, which has been designated MDL No. 2092.

Chantix side effects improperly reported

The mounting litigation comes as Pfizer, maker of the controversial smoking cessation aid, comes under fire for improperly reporting Chantix side effects to the FDA. In May, it was revealed that the company failed to promptly report 150 cases of Chantix suicide. Those Chantix suicides, since retroactively added to the FDAs adverse event record, more than doubles the total number of Chantix suicides reported by Pfizer, consumers and doctors.

On May 31, France announced it would no longer cover Chantix, which is sold as Champix overseas, under its state sponsored health program.